Acurx Pharmaceuticals, Inc. cotiza a 1.20 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patie…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.62 | $-0.31 | $-1.23 |
| Estimado | $-0.43 | $-0.63 | $-0.99 | $-1.48 |
| Sorpresa | — | +1.6% | +68.7% | +16.9% |
| Métrica | ACXP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -151.2% | -40.4% | -110.8% |
| ROA | -103.6% | -32.0% | -71.6% |
| Current Ratio | — | 2.84 | — |
| Debt / Equity | — | 0.28 | — |